WANY
CCCC icon

Wealthspire Advisors (New York)’s C4 Therapeutics CCCC Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$222 – 1328
2025
Q3 		$222 Buy
+100
New +$240 ﹤0.01% 2930

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Wealthspire Advisors (New York)'s CCCC Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 100 shares — an estimated $222 sold.

Wealthspire Advisors (New York) first reported a position in CCCC in Q3 2025 and held it in 1 quarter. The position peaked at $222 in Q3 2025. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 100 C4 Therapeutics shares in Q4 2025, an estimated $222.
  • Wealthspire Advisors (New York) first reported a position in C4 Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s C4 Therapeutics position peaked at $222 in Q3 2025.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.